# EDGAR Filing Document

**Accession Number:** 0001964166
**File Stem:** 0001140361-23-011729
**Filing Date:** 2023-3
**Character Count:** 33169
**Document Hash:** 86d454c9d7fb50817595f6b029d9ee9d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-23-011729.hdr.sgml**: 20230315

**ACCESSION NUMBER**: 0001140361-23-011729

**CONFORMED SUBMISSION TYPE**: SC TO-T/A

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20230315

**DATE AS OF CHANGE**: 20230315

**GROUP MEMBERS**: BIOSYNEX U.S. HOLDINGS, INC.

**GROUP MEMBERS**: PROJECT MERCI MERGER SUB, INC.

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CHEMBIO DIAGNOSTICS, INC.
- **CENTRAL INDEX KEY:** 0001092662
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 880425691
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-T/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-61925
- **FILM NUMBER:** 23733311

**BUSINESS ADDRESS:**
- **STREET 1:** 555 WIRELESS BLVD.
- **CITY:** HAUPPAUGE
- **STATE:** NY
- **ZIP:** 11788
- **BUSINESS PHONE:** (631) 924-1135

**MAIL ADDRESS:**
- **STREET 1:** 555 WIRELESS BLVD.
- **CITY:** HAUPPAUGE
- **STATE:** NY
- **ZIP:** 11788

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Chembio Diagnostics Inc.
- **DATE OF NAME CHANGE:** 20040607

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TRADING SOLUTIONS COM INC
- **DATE OF NAME CHANGE:** 19990805
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Biosynex SA
- **CENTRAL INDEX KEY:** 0001964166
- **IRS NUMBER:** 481075703
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-T/A

**BUSINESS ADDRESS:**
- **STREET 1:** 22 BOULEVARD SEBASTIEN BRANT
- **CITY:** ILLKIRCH-GRAFFENSTADEN
- **STATE:** I0
- **ZIP:** 67400
- **BUSINESS PHONE:** 33(0)670860015

**MAIL ADDRESS:**
- **STREET 1:** 22 BOULEVARD SEBASTIEN BRANT
- **CITY:** ILLKIRCH-GRAFFENSTADEN
- **STATE:** I0
- **ZIP:** 67400

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### SCHEDULE TO

#### TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)

#### OF THE SECURITIES EXCHANGE ACT OF 1934

#### (Amendment No. 2)

#### CHEMBIO DIAGNOSTICS, INC.

#### (Name of Subject Company (Issuer))

#### PROJECT MERCI MERGER SUB, INC.
(Offeror)

#### A wholly-owned indirect subsidiary of

## BIOSYNEX SA

#### (Parent of Offeror)

#### BIOSYNEX U.S. HOLDINGS, INC.

#### (Other Persons)

#### (Names of Filing Persons (identifying status as Offeror, Issuer or Other Person))

#### COMMON STOCK, PAR VALUE $0.01 PER SHARE

#### (Title of Class of Securities)

#### 163572209

#### (CUSIP Number of Class of Securities)

#### Alexis Steinmetz

#### c/o Biosynex SA

#### 22 Boulevard Sébastien Brant

#### 67400 Illkirch-Graffenstaden, France

#### +33 (0)6 70 86 00 15

#### (Name, address, and telephone numbers of person authorized to receive notices and

#### communications on behalf of filing persons)

#### &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

#### Copies to:

#### James Hu

#### Marc Petitier

#### White & Case LLP

#### 1221 Avenue of the Americas

#### New York, NY 10020
(212) 819-8200

☐ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

&nbsp;&nbsp;&nbsp;&nbsp;☒ Third-party tender offer subject to Rule 14d-1.

☐ Issuer tender offer subject to Rule 13e-4.

☐ Going-private transaction subject to Rule 13e-3.

☐ Amendment to Schedule 13D under Rule 13d-2.

Check the appropriate boxes below to designate any transactions to which the statement relates: ☐

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

☐ Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

☐ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

------

This Amendment No. 2 (this "Amendment") amends and supplements the Tender Offer Statement on Schedule TO (as amended and together with any subsequent amendments and supplements hereto, the "Schedule TO") filed by Biosynex SA, Inc., a French société anonyme ("Parent"), Biosynex U.S. Holdings, Inc., a Delaware corporation and a wholly-owned direct subsidiary of Parent ("Holdco"), and Project Merci Merger Sub, Inc., a Nevada corporation and a wholly-owned indirect subsidiary of Parent ("Purchaser") with the Securities and Exchange Commission on February 14, 2023. The Schedule TO relates to the tender offer for all of the issued and outstanding shares of common stock, par value $0.01 per share (the "Shares"), of Chembio Diagnostics, Inc. ("CEMI"), at a price of $0.45 per Share, net to the seller in cash without interest and subject to any required withholding taxes (the "Offer Price"), upon the terms and conditions set forth in the offer to purchase, dated February 14, 2023 (together with any amendments or supplements thereto, the "Offer to Purchase"), a copy of which is attached to the Schedule TO as Exhibit (a)(1)(A), and in the related letter of transmittal (together with any amendments or supplements thereto, the "Letter of Transmittal" and, together with the Offer to Purchase, the "Offer"), a copy of which is attached to the Schedule TO as Exhibit (a)(1)(B).

Except as otherwise set forth in this Amendment, the information set forth in the Schedule TO remains unchanged. This Amendment is being filed to reflect certain updates as reflected below. Capitalized terms used but not defined herein have the meanings assigned to such terms in the Offer to Purchase or the Schedule TO. You should read this Amendment together with the Schedule TO and the Offer to Purchase.

---

| | |
|:---|:---|
| **Items 1** | **through 9 and Item 11.** |

---

The Offer to Purchase and Items 1 through 9 and Item 11 of the Schedule TO, to the extent such Items incorporate by reference the information contained in the Offer to Purchase, are hereby amended and supplemented by adding the following paragraphs thereto:

"On March 15, 2023, Purchaser issued a press release announcing an extension of the Offer Expiration Time until 6:00 pm, New York City time, on March 28, 2023, unless the Offer is further extended or earlier terminated as permitted by the Merger Agreement. The Offer was previously scheduled to expire at one minute after 11:59 p.m., New York City time, on March 14, 2023.

The Depositary and Paying Agent has advised Purchaser that, as of 11.59 p.m., New York City time, on March 14, 2023, approximately 12,664,710 Shares have been validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 34.5% of the then-outstanding Shares.

Also on March 15, 2023, CEMI issued a press release and letter to stockholders.The press releases announcing the extension of the Offer are attached hereto as Exhibits (a)(5)(B) and (a)(5)(C) and incorporated herein by reference."

**#### Item 11.
The information set forth in Section 16 of the Offer to Purchase titled "Certain Legal Matters; Regulatory Approvals" and Item 11 of the Schedule TO, to the extent such item incorporates by reference the information contained in the Offer to Purchase, is hereby amended as follows:

*The "Legal Proceedings" subsection is amended and restated as follows (new language underlined and strikethrough language is deleted):*

On February 17, 2023, a complaint was filed in the United States District Court, Southern District of New York, against CEMI and the individual members of the CEMI Board and management, captioned Sholom Keller v. Chembio Diagnostics, Inc., Katherine L. Davis, John G. Potthoff, David W.K. Acheson, David W. Bespalko, Richard L. Eberly, Leslie Teso-Lichtman, and Lawrence J. Steenvoorden, Case No. 1:23-cv-01388 (the "*<u>New York</u> Complaint*"). <u>On March 8, 2023, a pro se complaint was filed in the United States District Court, District of Nevada, against CEMI and the individual members of the CEMI Board and management, captioned David S. Gross v. Chembio Diagnostics, Inc., Katherine L. Davis, John G. Potthoff, David W.K. Acheson, David W. Bespalko, Richard L. Eberly, Leslie Teso-Lichtman, and Lawrence J. Steenvoorden, Case No. 3:23-cv-00093 (the "</u>*<u>Nevada Complaint</u>*<u>, and together with the New York Complaint, the "</u>*<u>Complaints</u>*<u>").</u>** 

#### <br>

**The Complaint<u>s</u> asserts that the defendants violated Sections 14(d), 14(e), and 20(a) of the Exchange Act and certain rules and regulations promulgated thereunder by allegedly making false and misleading statements, or failing to disclose allegedly material facts necessary to make the statements made not misleading, relating to the Merger in the Schedule 14D-9, including allegations relating to the background of the Merger, financial projections, and analyses of Craig-Hallum.

In addition to the Complaint<u>s</u> referenced above, thirteen demand letters (the "Demands") have been received from purported stockholders of CEMI as of the date of this Amendment <u>No. 2</u>, each challenging certain of the disclosures in the Schedule 14D-9.** 

#### Amendments to the Offer to Purchase and Exhibits to the Schedule TO
All references to "one minute after 11:59 p.m., New York City time, on March 14, 2023" set forth in the Offer to Purchase (Exhibit (a)(1)(A)), Letter of Transmittal (Exhibit (a)(1)(B)), Letter from the Information Agent to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (Exhibit (a)(1)(C)), and Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (Exhibit (a)(1)(D)) are hereby amended and replaced with "6.00 p.m., New York City time, on March 28, 2023."

**Item 12.** **Exhibits.**<br>

Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibits:

---

| | |
|:---|:---|
| **Exhibit**<br> **No.** | **Description** |
| (a)(5)(B) | Press Release issued by Biosynex SA, dated March 15, 2023. |
| (a)(5)(C) | Press Release and Letter to Stockholders issued by Chembio Diagnostics, Inc., dated March 15, 2023. |

---

------

---

| | |
|:---|:---|
| **Exhibit**<br> **No.** | **Description** |
| [(a)(1)(A)\*](https://www.sec.gov/Archives/edgar/data/1092662/000114036123006920/ny20007172x2_exa1a.htm) | Offer to Purchase, dated February 14, 2023. |
| [(a)(1)(B)\*](https://www.sec.gov/Archives/edgar/data/1092662/000114036123006920/ny20007172x2_exa1b.htm) | Letter of Transmittal. |
| [(a)(1)(C)\*](https://www.sec.gov/Archives/edgar/data/1092662/000114036123006920/ny20007172x2_exa1c.htm) | Letter from the Information Agent to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. |
| [(a)(1)(D)\*](https://www.sec.gov/Archives/edgar/data/1092662/000114036123006920/ny20007172x2_exa1d.htm) | Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. |
| [(a)(1)(E)\*](https://www.sec.gov/Archives/edgar/data/1092662/000114036123006920/ny20007172x2_exa1e.htm) | Summary Advertisement, as published in the New York Times on February 14, 2023. |
| (a)(2) | Not applicable. |
| (a)(3) | Not applicable. |
| (a)(4) | Not applicable. |
| [(a)(5)(A)\*](https://www.sec.gov/Archives/edgar/data/1092662/000114036123003608/ny20007154x1_ex99-1.htm) | Joint Press Release issued by Chembio Diagnostics, Inc. and Biosynex SA, dated January 31, 2023 (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed with the SEC by Chembio Diagnostics, Inc. on January 31, 2023). |
| [(a)(5)(B)\*\*](brhc10049622_ex99-a5b.htm) | Press Release issued by Biosynex SA, dated March 15, 2023. |
| [(a)(5)(C)\*\*](brhc10049622_ex99-a5c.htm) | Press Release and Letter to Stockholders issued by Chembio Diagnostics, Inc., dated March 15, 2023. |
| (b) | Not applicable. |
| [(d)(1)](https://www.sec.gov/Archives/edgar/data/1092662/000114036123003608/ny20007154x1_ex2-1.htm) | Agreement and Plan of Merger, dated January 31, 2023, by and among Biosynex SA, Project Merci Merger Sub, Inc. and Chembio Diagnostics, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the SEC by Chembio Diagnostics, Inc. on January 31, 2023). |
| [(d)(2)\*](https://www.sec.gov/Archives/edgar/data/1092662/000114036123006920/ny20007172x2_exd2.htm) | Confidentiality Agreement, dated May 25, 2022, by and among Biosynex SA and Chembio Diagnostics, Inc. |
| (g) | None. |
| (h) | None. |
| [107\*](https://www.sec.gov/Archives/edgar/data/1964166/000114036123009456/ny20007172x3_ex107.htm) | Filing Fee Table. |

---

\* Previously filed.

\*\* Filed herewith.

#### <br>

------

#### SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: March 15, 2023

---

| | |
|:---|:---|
| **PROJECT MERCI MERGER SUB, INC.** | **PROJECT MERCI MERGER SUB, INC.** |
| By | /s/ Larry Abensur |
| Name: | Larry Abensur |
| Title: | President |
| **BIOSYNEX U.S. HOLDINGS, INC.** | **BIOSYNEX U.S. HOLDINGS, INC.** |
| By | /s/ Larry Abensur |
| Name: | Larry Abensur |
| Title: | President |
| **BIOSYNEX SA** | **BIOSYNEX SA** |
| By | /s/ Larry Abensur |
| Name: | Larry Abensur |
| Title: | Chief Executive Officer |

---

------

## Ex-99.(A)(5)(B)

------

**Exhibit (a)(5)(B)**<br>

#### Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.
**STRASBOURG, France, March 15, 2023 (GLOBE NEWSWIRE) --** Biosynex SA ("Biosynex") (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project Merci Merger Sub, Inc. ("Purchaser"), a Nevada corporation and its wholly-owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the "Shares") of Chembio Diagnostics, Inc. (Nasdaq: CEMI) ("Chembio") at a price of $0.45 per Share, net to the seller in cash, without interest and subject to any required tax withholding, until 6:00 p.m., New York City time on March 28, 2023, unless further extended. The tender offer was previously scheduled to expire at one minute after 11:59 p.m., New York City time, on March 14, 2023. All other terms and conditions of the tender offer remain unchanged.

Securities Transfer Corporation, the depositary and paying agent for the tender offer, has indicated that, as of 11:59 p.m., New York City time, on March 14, 2023, approximately 12,664,710 Shares had been validly tendered into and not validly withdrawn from the tender offer, representing approximately 34.5% of the Shares then outstanding. Stockholders who have already tendered their Shares into the tender offer do not have to re-tender their Shares or take any other action as a result of the extension of the expiration time of the tender offer.

Completion of the tender offer remains subject to additional conditions described in the Tender Offer Statement on Schedule TO (as amended or supplemented) filed by Purchaser and Biosynex with the U.S. Securities and Exchange Commission ("SEC") on February 14, 2023.

Requests for documents and questions regarding the tender offer may be directed to Alliance Advisors, LLC, the Information Agent for the tender offer, by telephone (toll-free) at 866-620-7692 or by email at CEMI@allianceadvisors.com.

#### About Biosynex

Founded in 2005 and based in Illkirch-Graffenstaden in Alsace, France, Biosynex is a major player in public health with 380 employees. Biosynex designs, manufactures and distributes Rapid Diagnostic Tests (RDTs) as well as diagnostic equipment for healthcare professionals and the general public, aiming to improve patient care through rapid results and ease of use. As the leader in the RDT market in France, Biosynex has complete control over its value chain thanks to its technological platform, which can be adapted to numerous applications and is suitable for different types of users such as laboratories, hospitals, doctors and consumers. Driven by strong values of innovation, Biosynex has a proactive vision of tomorrow's medicine focused on prevention, screening, emergency diagnosis and rapid treatment. Learn more at www.biosynex.com.

#### Additional Information and Where to Find It

This press release relates to a pending business combination between Biosynex and Chembio. This press release is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell shares of Chembio, nor is it a substitute for any tender offer materials that the parties have filed or will file with the SEC in connection with the tender offer. CHEMBIO STOCKHOLDERS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), THE SOLICITATION / RECOMMENDATION STATEMENT AND OTHER RELEVANT DOCUMENTS THAT HAVE BEEN AND MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO ANY OF THE FOREGOING DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF CHEMBIO SECURITIES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SECURITIES. The Solicitation/Recommendation Statement, the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents were sent to all of Chembio's stockholders at no expense to them. The tender offer materials and the Solicitation / Recommendation Statement are also available for free on the SEC's website at <u>www.sec.gov</u> or from the information agent named in the tender offer materials. Copies of the documents filed with the SEC by Chembio will be available free of charge under the SEC filings heading of the Investors section of Chembio's website at <u>https://chembio.com/investors</u>.

------

#### Forward Looking Statements

This press release contains forward-looking statements regarding the acquisition of Chembio Diagnostics, Inc. by Biosynex SA. Forward-looking statements involve inherent risks and uncertainties and you are cautioned that a number of important factors could cause actual results to differ materially from those contained in any such forward-looking statement. These statements can otherwise be identified by the use of words such as "anticipate," "believe," "could," "estimate," "expect," "feel," "forecast," "intend," "may," "plan," "potential," "predict," "project," "seek," "should," "would," "will," and similar expressions intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release include, but are not limited to, statements related to Biosynex's and Chembio's plans, objectives, expectations and intentions with respect to the proposed transaction and the combined company, the anticipated timing of the proposed transaction, the conditions precedent to the closing of the proposed transaction, and the potential impact the transaction will have on Chembio or Biosynex and other matters related to either or both of them. The forward-looking statements are based on assumptions regarding current plans and estimates of management of Biosynex and Chembio. Such management believes these assumptions to be reasonable, but there is no assurance that they will prove to be accurate.

Factors that could cause actual results to differ materially from those described in this press release include, among others: changes in expectations as to the closing of the transaction including timing and changes in the method of financing the transaction; the satisfaction of the conditions precedent to the consummation of the proposed transaction (including a sufficient number of Chembio shares being validly tendered into the tender offer to meet the minimum condition); the risk of litigation and regulatory action related to the proposed transactions; expected synergies and cost savings are not achieved or achieved at a slower pace than expected; integration problems, delays or other related costs; retention of customers and suppliers; and unanticipated changes in laws, regulations, or other industry standards affecting the companies; and other risks and important factors contained and identified in Biosynex's and Chembio's filings with the SEC, including Chembio's Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.

The foregoing list of factors is not exhaustive. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. Readers are urged to carefully review and consider the various disclosures, including but not limited to risk factors contained in Chembio's Annual Reports on Form 10-K and its quarterly reports on Form 10-Q, as well as other filings it and Biosynex have filed with the SEC. Forward-looking statements reflect the analysis of management of Biosynex and Chembio as of the date of this press release. Neither Biosynex nor Chembio undertakes to update or revise any of these statements in light of new information or future events, except as expressly required by applicable law.

#### For further information:

#### Biosynex Contacts:
Larry Abensur

Président-Directeur Général

#### investisseurs@biosynex.com

#### Julia Bridger
Listing Sponsor

+33 1 44 70 20 84

#### jbridger@elcorp.com

#### Gilles Broquelet
Communication financière

+ 33 1 80 81 50 00

#### gbroquelet@capvalue.fr

------

## Ex-99.(A)(5)(C)

------

#### Exhibit (a)(5)(C)<br>

#### <br>

#### <br> Chembio Announces Letter to Stockholders Regarding Tender Offer

MEDFORD, NY, March 15, 2023 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA.

March 15, 2023

Fellow Chembio Stockholders,

As previously disclosed, Chembio Diagnostics, Inc. ("Chembio" or the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 31, 2023, with Biosynex SA, a French société anonyme ("Biosynex"), and Project Merci Merger Sub, Inc., a Nevada corporation and wholly-owned indirect subsidiary of Biosynex (the "Purchaser"). Pursuant to the Merger Agreement, the Purchaser commenced a tender offer (the "Offer") to purchase all of the issued and outstanding shares of the Company's common stock, par value $0.01 per share (the "Shares"), for a purchase price of $0.45 per share, net to the seller in cash, without interest and subject to any required tax withholding.

The Offer was initially scheduled to expire at one minute after 11:59 p.m., New York City time, on March 14, 2023. Today, Biosynex announced an extension of the Offer until 6:00 p.m., New York City time, on March 28, 2023.

I believe Chembio is at a critical juncture and it is important to communicate the best available information to our stockholders at this time. The decision to enter into the Merger Agreement was arrived at following an extensive strategic review as detailed in the Schedule 14D-9 (the "Schedule 14D-9") filed with the U.S. Securities and Exchange Commission (the "SEC") on February 14, 2023.

As further disclosed in the Schedule 14D-9, the Company faces ongoing operational and financial challenges if it stays an independent company as a result of not enough Shares being tendered in the Offer and the transactions contemplated by the Merger Agreement not being consummated. These challenges include:

• ***<u>Credit Agreement; Debt Maturity and Covenants</u>***. Our Credit Agreement has a September 4, 2023 maturity date, and we do not currently believe that replacement debt or equity financing arrangements are or will be available to us or, if available to us, will be on acceptable terms. In addition, the Credit Agreement includes a minimum total revenue covenant, and based on our financial performance to date for the current quarter, we do not believe that we will be in compliance for the four fiscal quarters ended March 31, 2023. Our lender has previously informed us that it will not agree to any restructuring of the Credit Agreement, and as a result we may be forced to pursue a bankruptcy or restructuring proceeding when the debt matures (or earlier if the lender accelerates following a breach of the minimum total revenue covenant) or pursue a transaction or financing arrangement that could be dilutive to stockholders.

• ***<u>Potential Nasdaq Delisting</u>***. We do not anticipate meeting the minimum bid price requirement for continued listing on the Nasdaq Capital Market, and there is a strong likelihood that Nasdaq will notify the Company on or shortly after April 3, 2023 that it will be subject to delisting. While the Company may appeal a Nasdaq delisting determination to a Nasdaq hearings panel (and potentially seek time to pursue a reverse stock split or similar corporate action), there can be no assurance that any such appeal would be successful, particularly since we initially received a deficiency letter on April 5, 2022 and have already received a 180-day extension to regain compliance. Further, even if the Company were in a position to pursue a reverse stock split or other similar corporate action in an effort to regain compliance with the minimum bid requirement, there can be no assurance that it would be able to obtain the requisite stockholder approval under Nevada law. If the Company's common stock were to be delisted, this would adversely affect the Company's ability to publicly or privately sell equity securities and negatively impact the liquidity of your common stock.

------

![](image00001.jpg)

• ***<u>Net Losses and Going Concern Doubts</u>***. The Company's net loss of approximately $33.9 million for the year ended December 31, 2021 and $22.4 million for the nine months ended September 30, 2022 coupled with ongoing liquidity concerns have resulted in the Company's conclusion that there is substantial doubt about its ability to continue as a going concern.

As further described in the Schedule 14D-9, our Board of Directors (the "Board") unanimously determined that the Merger Agreement and the transactions contemplated by the Merger Agreement are in the best interests of stockholders and recommended that stockholders tender their shares in the Offer. As part of reaching this determination and recommendation, the Board considered the premium the offer price represented, the certainty the tender offer and merger would provide stockholders, and the business reputation, management and financial resources of Biosynex.

While the Board and management will continue to diligently serve the interests of the stockholders, I am writing to my fellow Chembio stockholders to reiterate the Board's recommendation for stockholders to tender their Shares. To the extent stockholders want to tender their Shares before the offer closes, they should contact Alliance Advisors at 866-620-7692 or CEMI@allianceadvisors.com.

Richard L. Eberly

President and Chief Executive Officer

#### About Chembio Diagnostics
Chembio is a leading diagnostics company focused on developing and commercializing point-of-care tests used to detect and diagnose infectious diseases, including sexually transmitted disease, insect vector and tropical disease, COVID-19 and other viral and bacterial infections, enabling expedited treatment. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.

#### Additional Information and Where to Find It
This press release relates to a pending business combination between Biosynex and Chembio. This press release is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell shares of Chembio, nor is it a substitute for any tender offer materials that the parties have filed or will file with the SEC in connection with the tender offer. CHEMBIO STOCKHOLDERS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), THE SOLICITATION / RECOMMENDATION STATEMENT AND OTHER RELEVANT DOCUMENTS THAT HAVE BEEN AND MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO ANY OF THE FOREGOING DOCUMENTS CAREFULLY THAT ARE OR BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF CHEMBIO SECURITIES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SECURITIES. The Solicitation/Recommendation Statement, the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents were sent to all of Chembio's stockholders at no expense to them. The tender offer materials and the Solicitation / Recommendation Statement are also available for free on the SEC's website at www.sec.gov or from the information agent named in the tender offer materials. Copies of the documents filed with the SEC by Chembio are available free of charge under the SEC filings heading of the Investors section of Chembio's website at https://chembio.com/investors.

------

#### <br>

#### Forward Looking Statements
This press release contains forward-looking statements regarding the acquisition of Chembio Diagnostics, Inc. by Biosynex SA as well as the matters in the bullet points captioned "Credit Agreement; Debt Maturity and Covenants," "Potential Nasdaq Delisting" and "Net Losses and Going Concern Doubts". Forward-looking statements involve inherent risks and uncertainties and you are cautioned that a number of important factors could cause actual results to differ materially from those contained in any such forward-looking statement. These statements can otherwise be identified by the use of words such as "anticipate," "believe," "could," "estimate," "expect," "feel," "forecast," "intend," "may," "plan," "potential," "predict," "project," "seek," "should," "would," "will," and similar expressions intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release include, but are not limited to, statements related to Biosynex's and Chembio's plans, objectives, expectations and intentions with respect to the proposed transaction and the combined company, the anticipated timing of the proposed transaction, the conditions precedent to the closing of the proposed transaction, and the potential impact the transaction will have on Chembio or Biosynex and other matters related to either or both of them. The forward-looking statements are based on assumptions regarding current plans and estimates of management of Biosynex and Chembio. Such management believes these assumptions to be reasonable, but there is no assurance that they will prove to be accurate.

Factors that could cause actual results to differ materially from those described in this press release include, among others: changes in expectations as to the closing of the transaction including timing and changes in the method of financing the transaction; the satisfaction of the conditions precedent to the consummation of the proposed transaction (including a sufficient number of Chembio shares being validly tendered into the tender offer to meet the minimum condition); the risk of litigation and regulatory action related to the proposed transactions; expected synergies and cost savings are not achieved or achieved at a slower pace than expected; integration problems, delays or other related costs; retention of customers and suppliers; and unanticipated changes in laws, regulations, or other industry standards affecting the companies; and other risks and important factors contained and identified in Biosynex's and Chembio's filings with the SEC, including Chembio's Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.

The foregoing list of factors is not exhaustive. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. Readers are urged to carefully review and consider the various disclosures, including but not limited to risk factors contained in Chembio's Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q, as well as other filings it and Biosynex have filed with the SEC. Forward-looking statements reflect the analysis of management of Biosynex and Chembio as of the date of this press release. Neither Biosynex nor Chembio undertakes to update or revise any of these statements in light of new information or future events, except as expressly required by applicable law.

#### Contact:
Philip Taylor

Gilmartin Group

415-937-5406

<u>investor@chembio.com</u>

------